Showing results (1671-1680 of 1,712) with videos related to

Sort By:
Pageof 172
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|January 28, 2006
[Comparison of clinical and surgico-pathological TNM stage of 2007 lung cancer patients]Guo-jun Huang, De-chao Zhang, You-sheng Mao, et al.
Journal of the American Chemical Society|December 5, 2008
Large-scale synthesis of single-crystalline iron oxide magnetic nanoringsChun-Jiang Jia, Ling-Dong Sun Sun, Feng Luo, et al.
Gut|March 24, 2019
Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockadeYing Zhu, Jing Yang, Da Xu, et al.
Signal Transduction and Targeted Therapy|May 6, 2026
Sintilimab (PD-1 inhibitor) plus lenvatinib as conversion therapy followed by sequential surgery (SILENSES) for advanced unresectable hepatocellular carcinoma: a phase II, expansion trialShichun Lu, Wenwen Zhang, Junfeng Li, et al.
Nature Communications|May 22, 2023
Geometry design of tethered small-molecule acceptor enables highly stable and efficient polymer solar cellsYang Bai, Ze Zhang, Qiuju Zhou, et al.
Gut|February 9, 2026
MTFP1 drives pancreatic cancer liver metastatic colonisation by regulating mitochondrial metabolism reprogrammingYang Chen, Gao-Wei Jin, Li-Hong He, et al.
Advanced Materials (Deerfield Beach, Fla.)|February 22, 2021
Co and Pt Dual-Single-Atoms with Oxygen-Coordinated Co-O-Pt Dimer Sites for Ultrahigh Photocatalytic Hydrogen Evolution EfficiencyCong Wang, Kaiwen Wang, Yibo Feng, et al.
National Science Review|August 23, 2024
An orbital strategy for regulating the Jahn-Teller effectTongtong Shang, Ang Gao, Dongdong Xiao, et al.
Journal for Immunotherapy of Cancer|September 20, 2023
Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trialWenwen Zhang, Shuang Tong, Bingyang Hu, et al.
Oncotarget|October 4, 2017
Early postoperative radiotherapy is associated with improved outcomes over late postoperative radiotherapy in the management of completely resected (R0) Stage IIIA-N2 non-small cell lung cancerHuan-Huan Wang, Lei Deng, Qing-Lian Wen, et al.
Pageof 172